Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Shares Issued Shares Outstanding Shares Outstanding

Ratios

Viking Therapeutics (VKTX) Shares Repurchased (2022)

Viking Therapeutics (VKTX) has disclosed Shares Repurchased for 2 consecutive years, with $1.7 million as the latest value for Q2 2022.

For Q2 2022, Shares Repurchased changed N/A year-over-year to $1.7 million; the TTM value through Dec 2022 reached $6.8 million, changed N/A, while the annual FY2022 figure was $6.8 million, N/A changed from the prior year.
Shares Repurchased hit $1.7 million in Q2 2022 for Viking Therapeutics, down from $5.1 million in the prior quarter.
Across five years, Shares Repurchased topped out at $5.1 million in Q1 2022 and bottomed at $1.7 million in Q2 2022.